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Abstract
Background: Plasma concentrations of C-reactive protein (CRP), a marker of chronic inflammation, have been associated
with cognitive impairment in old age. However, it is unknown whether CRP is causally linked to cognitive decline.
Methods and Findings: Within the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial, with 5680
participants with a mean age of 75 years, we examined associations of CRP levels and its genetic determinants with
cognitive performance and decline over 3.2 years mean follow-up. Higher plasma CRP concentrations were associated
with poorer baseline performance on the Stroop test (P = 0.001) and Letter Digit Tests (P,0.001), but not with the
immediate and delayed Picture Learning Test (PLT; both P.0.5). In the prospective analyses, higher CRP
concentrations associated with increased rate of decline in the immediate PLT (P = 0.016), but not in other cognitive
tests (all p.0.11). Adjustment for prevalent cardiovascular risk factors and disease did not change the baseline
associations nor associations with cognitive decline during follow-up. Four haplotypes of CRP were used and,
compared to the common haplotype, carrierships associated strongly with levels of CRP (all P,0.007). In comparison
to strong associations of apolipoprotein E with cognitive measures, associations of CRP haplotypes with such
measures were inconsistent.
Conclusion: Plasma CRP concentrations associate with cognitive performance in part through pathways independent of
(risk factors for) cardiovascular disease. However, lifelong exposure to higher CRP levels does not associate with poorer
cognitive performance in old age. The current data weaken the argument for a causal role of CRP in cognitive performance,
but further study is warranted to draw definitive conclusions.
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Introduction
Plasma concentrations of C-reactive protein (CRP), a marker of
chronic inflammation, have been associated with numerous
clinical conditions, including cognitive decline in old age.
However, although some epidemiological studies indeed suggest
an association of high concentrations of CRP with risk of dementia
or cognitive decline [1–6], the data are not consistent [7,8]. A
meta analysis [9] suggested an association with cognitive
impairment, but to date causality is uncertain.
Investigation of mechanisms linking CRP to cognitive decline in
humans is hampered by the inability to distinguish cause from
effect in conventional association studies. Whether CRP directly
causes cognitive decline in the brain is not well examined.
Speculatively, CRP may indirectly lead to cognitive impairment
via promoting vascular disease i.e. causing stroke and transient
ischemic attacks (TIAs), although recent genetic studies go against
CRP as a causal agent in vascular disease [10]. In another
hypothesis CRP is produced as a result of the inflammatory
process linked to a plethora of lifestyle factors (e.g. obesity,
smoking, poor diet, lack of activity etc.) and is therefore simply a
by-product linked to adverse lifestyle. So far, only few studies have
considered all such possibilities or had the ability to take into
account cardiovascular disease, risk factors and genetic determi-
nants of CRP as means of testing causality.
Within the Prospective Study of Pravastatin in the Elderly at
Risk (PROSPER) trial - a trial of pravastatin versus placebo
among 5804 men and women, who were 70 to 82 years of age [11]
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- we associated plasma CRP concentrations with cognitive decline
and investigated to what extent cardiovascular risk factors explain
this association. Second, we investigated the effects of genetically
determined elevated CRP concentrations as a proxy for lifelong
higher CRP concentrations on risk of cognitive decline in old age,
and compared such associations to known effects of apolipoprotein
E (APOE) on cognitive measures as an internal ‘‘positive’’ control.
Methods
Study design and participants
PROSPER (Prospective Study of Pravastatin in the Elderly at
Risk) was a trial of statin use in preventing coronary and
cerebrovascular events in older subjects either with a previous
history of vascular disease or at high risk of an event due to a
history of smoking, hypertension or diabetes [11]. Subjects aged
70–82 years were recruited in Scotland, Ireland and the Nether-
lands and randomized to receive 40 mg pravastatin or placebo
daily. There were restrictions on entry: plasma cholesterol had to
be in the range 4.0–9.0 mmol/l and triglyceride ,6.0 mmol/l. A
cut off score of 24 points or more (out of 30) on the Mini Mental
State Examination (MMSE) at baseline was used as an inclusion
criterion to eliminate those with poor cognitive function at
baseline. Statin use did not affect cognitive decline during the
study period [12]. The study was approved by the institutional
ethics review boards of centres of Cork University (Ireland),
Glasgow University (Scotland) and Leiden Univeristy Medical
Center (the Netherlands) and all participants gave written
informed consent.
Measurements
Plasma concentrations of cholesterol, triglyceride, low density
lipoprotein (LDL) cholesterol and high density lipoprotein (HDL)
cholesterol were measured twice at fasting visits during the placebo
run-in phase in a central laboratory which was standardised
through the Center for Disease Control network. Apolipoprotein E
phenotype was determined on plasma samples by Western blotting
following the method of Havekes et al [13]. Subjects were
classified according to the presence of the E2, E3 or E4 bands on
gel blots. CRP was measured on stored (at 280uC) and previously
unthawed samples by automated particle-enhanced immunotur-
bidimetric assay (Roche, UK). The method has inter and intra-
assay coefficient of variation of ,3%. Our laboratory participates
in a national external quality control for high sensitivity CRP. All
samples were processed by technicians blinded to the identity of
samples. CRP measurements were available for 5680 participants.
Prevalent disease
Diabetes at baseline was defined by self-reported history, a
fasting blood glucose measurement of $7.0 mmol/l, or in the 5%
of subjects that did not fast, a non-fasting blood glucose
measurement of $11.1 mmol/l, or self-reported use of anti-
diabetic medications (any oral hypoglycaemic or insulin). Hyper-
tension at baseline was defined by self-reported history; blood
pressure was measured at baseline. Smoking was defined as
current smoking at baseline. History of cardiovascular disease
(myocardial infarction, stroke/TIA or vascular) was defined as self-
reported at baseline. Level of education was assessed by the age
the participant left school.
Genotyping
Three single nucleotide polymorphisms (SNPs) in the CRP gene
were selected (table 1) that have previously been associated with
concentrations of CRP. Genotyping was carried out using
TaqManH SNPs genotyping assays (Applied Biosystems, Foster
City, CA). The endpoint was read after PCR amplification using
an Applied Biosystems 7900 HT Sequence Detection System.
Genotypes with quality scores below the 95% were repeated and
5% blinded replicates for genotype determinations were per-
formed. All three polymorphisms were in Hardy-Weinberg
equilibrium (all P.0.17) and were available for all 5680
participants.
Cognitive test battery
A detailed description of the cognitive tests used in the study has
been published earlier [14]. The Mini Mental State Examination
(MMSE) is used widely to screen for cognitive impairment.
Memory was tested using the Picture-Word Recall test based on
the Groningen-Fifteen Words test [15]. This measures recall, both
immediate and after 20 minutes, of 15 pictures. The outcome
variable is the mean number of correctly recalled pictures over
three immediate trials and number recalled after the delay.
Attention and processing were assessed using the Stroop-Colour
Word test and the Letter-Digit Coding test [14]. The former, in
the key Part III of the test, presents colour names printed in
incongruously coloured ink (e.g. the word ‘green’ printed in blue
ink). Performance, timed in seconds to complete the test, measures
the ability to discard the irrelevant name (green) in favour of the
colour of the ink (blue). The latter asks the subject to fill in digits
next to letters according to a key and the outcome is the number of
correct entries in 60 seconds. Subjects were assessed with al tests
twice (two weeks apart) at baseline to allow for any training effect.
The results of the second test were taken as the starting estimate of
cognitive function. All tests were repeated at 9, 18 and 30 months,
and at final trial visit. The time point of this last measurement was
different for the participants (at 36–48 months), therefore we
performed the analyses with their individually varying time-point
but report the results for the mean of these time points (at 42
months).
Statistical analyses
The distribution of CRP was skewed and therefore a
logarithmic transformation was used. Means and standard
deviations were used to assess central tendency of normally
distributed variables, whereas median and interquartile range were
used for variables that were not normally distributed.
The program Haploview [16] was used to estimate the allele
frequencies, test the consistency of the genotype frequencies at
each SNP locus with Hardy–Weinberg equilibrium, and estimate and
plot pairwise linkage disequilibrium (LD) between the SNPs
examined. Haplotypes and haplotype frequencies were calculated
using SNPHAP software (http//www-gene.cimr.cam.ac.uk/clayton/
software, 2006). We used multiple imputation analysis to
account for many haplotype probabilities per subject. This
method has been described elsewhere in more detail [17].
Table 1. Selected polymorphisms in the CRP gene.
rs-number
Position
in gene Coding Alleles
Minor allele
frequency
rs1417938 Intron 1 No T/A 0.297
rs1800947 Codon 184 Synonymous G/C 0.060
rs1205 39UTR No C/T 0.330
Minor alleles are underlined.
doi:10.1371/journal.pone.0023890.t001
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Imputed haplotypes with frequencies below 5% are included in
the models to ensure the use of all data. Associations with this
combined group are however not reported, as inferences are
hard to make from associates with this heterogeneous groupThe
haplotype analysis approach used in this study assumes an
additive effect of the haplotypes, and details of this approach
have been described elsewhere [18].
To assess the relation between CRP concentrations, CRP
haplotypes and cognitive function, we used linear mixed models.
Mixed models use all available data during multiple visits during
follow up, can properly account for correlation between repeated
measurements, and can handle missing data more appropriately
than traditional models. They allow for the use of time
independent and time dependent covariates [19].
Baseline cognitive performance per tertile of CRP concentration
was calculated using a linear regression model. The rate of cognitive
decline during follow-up dependent on CRP tertile (‘accelerated
cognitive decline’) was calculated with the interaction term between
tertile of CRP with study visit in the linear mixed model, assessing
whether cognitive decline is steeper in any of the tertiles.
To assess the relationship between CRP haplotypes with
cognitive performance we used linear mixed models in a different
way. For each cognitive test ‘mean difference over the study
period’ was calculated between haplotypes of CRP, comparing the
mean cognitive performance at all study visits per haplotype of
CRP. Multiple imputation was used to account for haplotype
probabilities. The model assumes that the effect of CRP genotypes
on cognition exists throughout the lifetime, with a resulting
difference in cognitive performance during the entire study period.
All models were adjusted for age, sex and country of inclusion.
The baseline association of CRP concentrations and cognition was
additionally adjusted for level of education and APOE genotype.
In the prospective analyses of the association of CRP concentra-
tions with the rate of cognitive decline we additionally adjusted for
study allocation (pravastatin or placebo). To assess the relationship
with classical risk factors for atherosclerosis, models additionally
included cardiovascular risk factors history of diabetes, hyperten-
sion, myocardial infarction, stroke, TIA or vascular disease,
LDL- and HDL-cholesterol, triglycerides, systolic and diastolic
blood pressure. The associations of CRP haplotypes with cognition
were adjusted for age, sex, country of inclusion, study allocation
(pravastatin or placebo) and APOE genotype.
All analyses were performed using SPSS version 16.0.
Results
Baseline characteristics
Baseline characteristics of study participants have been
described in detail elsewhere [11] In short, the present analysis
included 5680 participants of which 2936 (52%) were female.
Mean age at baseline was 75.3 years (range 70–82). Mean CRP
concentration was 3.1 mg/L.
C-reactive protein concentration and cognitive
performance
At baseline, higher concentrations of CRP were associated with
worse performance on the Stroop and Letter Digit coding Test
(LDT) (table 2). No such association was observed with the
immediate and delayed Picture Learning Test (PLTi and PLTd).
The observed associations with LDT and Stroop were indepen-
dent of age, gender, level of education, country, treatment
allocation and APOE genotype as the model was adjusted for
these factors. Additional adjustment for a history of cardiovascular
disease as well as classical cardiovascular risk factors did not affect
these associations. During follow-up higher concentrations of CRP
associated with an increased rate of cognitive decline measured
only with the immediate PLT (P=0.016), but not in the other
cognitive tests (table 2). Again, adjustment for cardiovascular risk
factors did not affect the association.
CRP haplotypes And association with crp concentration
and cognition
Allele frequencies of the three SNPs are listed in table 1. The
three CRP polymorphisms constituted one block in tight linkage
disequilibrium with four common haplotypes TGC (frequency 0.37)
AGC (frequency 0.30), TGT (frequency 0.27) and TCT (frequency
0.06). Association of the haplotypes with plasma concentrations of
Table 2. Association of circulating concentrations of CRP with cognitive test performance at baseline.
Cognitive test, mean (95% CI) Tertile of CRP concentration P for trend
Low Intermediate High basic adjusted
,2.0 mg/L 2.0–4.8 mg/L .4.8 mg/L model* model{
n=1893 n=1896 n=1891
Stroop (seconds to perform task) Baseline score 65.3 (63.5; 67.2) 66.3 (64.4;68.2) 67.6 (65.7;69.5) 0.001 0.007
Annual change +0.78 (+0.56;+1.00) +0.48 (+0.26;0.70) +0.77 (+0.52;+1.02 0.698 0.697
LDT (letters coded) Baseline score 23.8 (23.3;24.3) 23.3 (22.8;23.8) 22.9 (22.4;23.4) ,0.001 ,0.001
Annual change 20.44 (20.49;20.39) 20.28 (20.33;20.24) 20.36 (20.42;20.31) 0.167 0.173
PLTi (pictures recalled) Baseline score 9.4 (9.2–9.5) 9.4 (9.3;9.6) 9.4 (9.3;9.5) 0.577 0.461
Annual change 20.01 (20.03;+0.01) 20.01 (20.03;+0.01) 20.05 (20.07;20.02) 0.016 0.016
PLTd (pictures recalled) Baseline score 10.2 (10.0;10.4) 10.3 (10.1;10.5) 10.2 (10.0;10.4) 0.604 0.909
Annual change 20.07 (20.10;20.04) 20.07 (20.10;20.04) 20.07 (20.10;20.04) 0.109 0.108
Mean scores on cognitive test battery were calculated at baseline using a linear regression model with tertiles of CRP as independent variable. Statistical significance of
the trend was calculated using this model with CRP concentrations as continuous variable.
*Adjusted for gender, age at baseline, study site, level of education, treatment allocation (none at baseline), APOE genotype, and (if applicable) version of test used.
{Additionally adjusted for history of hypertension, diabetes, vascular disease, myocardial infarction, stroke or transient ischemic attack, body mass index, systolic and
diastolic blood pressure, smoking, LDL- and HDL-cholesterol, triglycerides.
doi:10.1371/journal.pone.0023890.t002
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CRP are shown in figure 1. Compared to the most frequent
haplotype TGC, AGC associated with a higher plasma concentra-
tion of CRP (P= 0.007), whereas TGT and TCT associated with
significantly lower concentrations of CRP (both P,0.001). The
association of haplotypes of CRP with cognitive performance is
shown in figure 2 (left panel). Compared to the most frequent
haplotype TGC, AGC (and so higher CRP concentrations) was
associated with better (not worse) performance on the PLTd
(P=0.044). The TGT haplotype did not associate with different
cognitive performance on any test, compared to TGC. The
TCT haplotype associated with better performance on both the
delayed (P=0.044) and immediate (P=0.039) picture learning test.
However, although highly statistically significant, the effect size of
the association of CRP haplotypes with CRP concentrations is small.
For instance, the TCT haplotype with the biggest difference with
respect to CRP concentrations compared to the reference haplotype
TGC had 0.35 logCRP lower levels (figure 1). For the cognitive test
that associated the strongest with CRP concentrations (LDT), we
calculated that this would lead to an expected effect of 0.12 points.
From figure 2 it can be concluded that the estimates and especially
the wide confidence intervals of the observed differences overlaps
this expected estimate. We conclude that our study is underpowered
to use the CRP haplotypes as an instrumental variable in a
Mendelianrandomization approach. To give reader some sense of
the magnitude of the association we used the APOE epsilon2/3/4
polymorphism as a positive control, to validate that using this
approach we were able to find associations of common genotypes
with cognitive performance using this cognitive test battery in this
population. Figure 2 (right panel) shows an association of the APOE
epsilon 4 allele with worse cognitive performance compared to the
epsilon 3 allele, as measured with the Stroop (P=0.001), LDT
(P=0.007), PLTi (P,0.001) and PLTd (P,0.001).
Discussion
This study has two main findings. First, whereas there was
substantial association of plasma CRP concentrations with
cognitive performance in the cross-sectional analyses, the associ-
ation was only minimal in the longitudinal analysis (which, given
that tests are repeated within individuals, is perhaps a more
rigorous test of association). In each case, observed associations
were not affected by adjustment for cardiovascular risk factors or
baseline vascular disease status. Second, although there was strong
association between CRP haplotypes with CRP concentrations, the
CRP genotype did not associate strongly (all P$0.039) or
consistently in the hypothesized direction with cognitive decline,
in stark contrast to the observed more robust (all P#0.007)
and directionally consistent effects of apolipoprotein E (APOE)
polymorphisms on cognition.
There are a number of explanations how circulating concen-
trations of CRP would associate with cognitive performance.
There may be a direct causal effect of CRP inflicting damage
locally in the brain. As CRP is not produced locally in the brain,
this theory is dependent on the assumption that the blood-brain-
barrier is permeable for CRP. Alternatively, CRP may indirectly
influence cognition via potential effects on vascular disease.
However, we found limited and inconsistent associations of
haplotypes of CRP with cognitive function in a large population
which has been exposed for over 70 years to germline determined
(hence unconfounded, [20]) differential concentrations of plasma
CRP. However, definitive conclusion cannot be drawn as power in
our study was limited. A recent Mendelian Randomization study
by Zacho [10] already reported no association of genetic variants
in the CRP gene with cardiovascular disease. More recently, no
association was observed of variants in the CRP gene with
cognitive performance in old age in over four thousand individuals
in four Scottish cohorts [21]. However, the four cohorts were
heterogeneous in population selection, as were their measures of
cognitive performance. These points leave room for speculation
that this heterogeneity may have obscured an existing association.
Furthermore, genetic association studies need replication. Our
study now replicates in a large cohort the findings of Marioni.
Furthermore, in our own study statins, that are known to reduce
concentrations of CRP did not affect cognitive function, although
we do not have repeated CRP measurements in our cohort. Taken
together, these data currently do not support a role for CRP in
cognitive decline, either directly causal or indirectly as a causative
factor in vascular disease, but further study is necessary to draw
definitive conclusions.
If CRP itself is not directly causal in cognitive decline,
concentrations of CRP may be the read-out of mechanisms that
causes cognitive decline. Again, cardiovascular disease and
associated risk factors and lifestyle factors are the most likely
candidates. Atherosclerosis may be regarded as a pro-inflamma-
tory condition [22] and is also a consequence of cardiovascular risk
factors such as diabetes mellitus, high blood pressure, and
dyslipidaemia, which are all risk factors for cognitive decline
[23] and are likewise associated with circulating concentrations of
CRP [24]. We report here an association of concentrations of
CRP with cognitive performance at baseline, and with an
increased rate of cognitive decline during follow-up, at least in
one cognitive domain. This association was however unaffected by
adjustment for cardiovascular risk factors, suggesting that
cardiovascular disease or risk factors, at least as measured, are
not the simple explanations for the observed associations. Of
course there may be residual confounding by unmeasured factors
which raise CRP and also cause cognitive decline. We also cannot
discount a reverse causal mechanism whereby an increased CRP is
contributed to by cognitive decline; cognitive decline is associated
with a poor nutritional status and increase in incident diseases,
which in turn could lead to an increased plasma CRP
concentration. Thus, although we see some associations of CRP
with some domains of cognitive performance with decline, these
observational data cannot establish causality.
Using known CRP polymorphisms, we noted a strong
association between haplotypes of CRP with CRP concentration.
Figure 1. Association of CRP haplotypes with plasma concen-
trations of CRP. Data represent mean (dots) and 95% confidence
interval (bars) of the difference in logarithmized CRP concentration of
the different CRP haplotype as compared with the reference TGC
haplotype.
doi:10.1371/journal.pone.0023890.g001
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The magnitude of these associations were, however, small and did
not allow to perform a Mendelianrandomization analysis. We used
the APOE epsilon 2/3/4 polymorphism as a positive control or
benchmark, to illustrate that our approach is suitable to detect
significant differences in cognitive performance. Interestingly, the
APOE 2/3/4 alleles also associate with concentrations of CRP but
we were carefully to adjust for APOE genotype in models linking
CRP to cognitive measures. The epsilon 4 allele is associated with
cognitive decline in many studies, including the one under study
[25], thus providing some external validity of PROSPER findings.
Based on our analysis, however, we cannot make definitive
conclusions, which will have to come from studies large enough to
perform a mendelianrandomization, and will likely have to involve
a number of participants that is far greater than our cohort.
The present study adds to current understanding in two ways.
First, we report on prospective follow-up of cognition in a cohort
of over five thousand elderly, yielding a high power to measure the
actual rate of cognitive decline within the individual. This
approach is more robust to detect cognitive decline than
cross-sectional association studies of CRP with cognition, as the
latter studies are more vulnerable to confounding and individual
variance in test performance. Second, this is the largest study we
are aware to study the association of CRP genotypes with cognitive
decline. These two aspects together substantially lessen support for
CRP as causal agent in cognitive decline and as a consequence
suggest a need for new thinking in this area of research. Besides
larger studies as mentioned above, more research is warranted in
the ‘upstream’ mechanisms/pathways causing CRP to rise
concomitantly with cognitive decline, for example an examination
of pro-inflammatory cytokines. We recognize, however, that our
data require replication in other cohorts. Exclusion of elderly with
an MMSE below 24 point at baseline, may have further reduced
our power to detect changes in cognitive function. The observed
associations between CRP concentrations and cognitive test scores
do not allow for clinical utility as the effect sizes are small.
In conclusion, although CRP concentrations relate strongly to
baseline executive function (Stroop and LDT) in the elderly,
associations with annual change are less impressive and haplotypes
of CRP that associate strongly with plasma CRP concentrations do
not consistently associate with cognitive performance or decline in
old age, in stark contrast to APOE genotype. The overall results
argue against a causal role for CRP in cognitive performance or
decline in older age, although more research is needed to provide
definitive answers.
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